Merck & Co. Licenses Endocyte’s Phase III Cancer Drug for a Potential US$1 B
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 23 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1728 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS